



# Developing a World-Class Pure Play Cannabis Company

**MMJ PhytoTech Limited (ASX. MMJ)**

**2016 Annual General Meeting Presentation**

ALL CURRENCY AMOUNTS ARE IN CAD UNLESS STATED OTHERWISE.

## DISCLAIMER

This presentation has been prepared by PhytoTech Medical Limited (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

## FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

## US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

## ***A Transformational Year for MMJ***

- MMJ is the first ASX-listed company to become a Licensed Producer under Marihuana for Medical Purposes Regulations – framework now known as Access to Cannabis for Medical Purposes Regulations (“ACMPR”)
- Execution of a binding term sheet with Canadian-based Harvest One Capital Corp. (“Harvest One”) (TSXV NEX: WON. H) for the sale to Harvest One of 100% of the issued shares of UG and Satipharm
- Import Permit received enabling importation of 1kg of cannabis seeds, which paves the way for commencement of cultivation at Duncan Facility in December 2016
- United Greeneries executed a binding letter of intent (“LOI”) with Cowichan Tribes in respect to the leasing of a 13-acre strategic land package (“Expansion Land”) located immediately adjacent to the Company’s existing Duncan Facility
- Positioned company for entry into evolving Australian market with signing of strategic partnerships with Australian dispensary, Fresh Therapeutics Compounding Pharmacy, and Epilepsy Action Australia
- Strengthening of pharmaceutical experience with appointment of Stanislav Sologubov as CEO of Satipharm AG and Catherine Harvey as Chief Operating Officer of MMJ
- Israel subsidiary, PhytoTech Therapeutics (PTL), successfully completed Phase 1 Clinical Trial highlighting the safety and performance of Gelpell-CBD capsules
- PTL Phase 2 Clinical Trial into treatment of pediatric epilepsy to commence imminently

## ***MMJ shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector***

### ***Driving shareholder value in Canada***

- MMJ PhytoTech ('MMJ' or the 'Company') to list Canadian subsidiary United Greeneries ('UG') together with Swiss subsidiary Satipharm ('SAT') on the TSX Venture Exchange ('TSX-V') (the "Transaction").
- MMJ has executed a binding term sheet with Canadian-based Harvest One Capital Corp. ("Harvest One") (TSXV NEX: WON. H) for the sale to Harvest One of 100% of the issued shares of UG and Satipharm
- Harvest One proposal includes total consideration for UG assets of C\$42M - \$40M equity (53.3M shares @ \$0.75/share) and \$2M cash
- Pro Forma ownership of TSX listed entity approx. 70%
- The proposed TSX-V listing is designed to allow for greater direct market value comparisons between MMJ's world-class cannabis assets and existing TSX-V listed cannabis producers
- Robust appetite for cannabis-focused equities – circa **C\$200M** raised by MMJ's Canadian peers since March 2016
- MMJ expects the transaction to be finalised and the resulting issuer to be traded on the TSX-V in Q1 2017

***Targeting First-Mover  
Advantage in a  
Pioneering Market***

- MMJ focused on major expansion opportunity in Canadian medical and future recreational markets, estimated to grow to C\$8b p.a. by 2024
- The Canadian medical cannabis market is one of the most highly regulated and favourable operating jurisdictions globally
- At present, there are 34 approved LP's operating under the current regulatory framework, of which only 10 are publicly listed in Canada
- Health Canada has recently instated a specialist Task Force focused on marijuana legalisation and regulation. The Task Force will consult with key stakeholders including government bodies, industry representatives and members of the community to provide advice on the design and implementation of new legislative and regulatory framework
- The Canadian government has committed to the introduction of the new regulatory system by in the second half of calendar 2017, with full implementation soon after



- On 30 June 2016, Health Canada (“HC”) officially approved UG as an authorised Licensed Producer (“LP”) at the Company’s flagship Duncan Facility
- The Duncan Facility is a state of the art Medical Cannabis operation with circa 10,000ft<sup>2</sup> of cultivation area
- UG will undertake the staged expansion of the Duncan Facility, with initial production of circa 7,500kg of cannabis by the end of 2018, following the facility’s first full year of production
- UG plans to then rapidly scale up the production capacity of the Duncan Facility to circa 60,000kg by 2022
- Highly scalable production will enable penetration of soon to be legalized Canadian recreational market while also servicing the existing legal medical market
- Lucky Lake Facility is a 62,000 ft<sup>2</sup> modern, concrete agricultural facility sitting on over 18 acres of land which is 100% owned by UG. ACMPR licensing is currently at the security clearance stage

**Focused on becoming large-scale cannabis producer targeting supply to rapidly expanding Canadian medical and recreational markets**




**Figure 1: Duncan's State of the art cultivation area.**



**Figure 2: Duncan Facility automated fertilizer system.**

**Low-cost, highly scalable production capacity targeting approx. 60,000 kg/year cannabis by 2022**



 **Made in Switzerland**

- Based in Switzerland, Satipharm is a pioneer in the development and distribution of medical cannabis based pharmaceutical, nutraceutical and cosmetics products.
- Satipharm has developed the ‘first and only’ product on the market with a pharmaceutical grade GMP (Good Manufacturing Product) production – unique GelPell® Microgel Capsules.
- Satipharm’s vision is to become a global leading company through the development and commercialization of its cannabidiol based products.
- Satipharm commenced production of its Gelpell Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.
- Satipharm is currently preparing a significant marketing campaign to drive sales of 10 MG and 50 MG capsules commencing October focusing first on Germany and Poland followed by entry into 10 additional EU countries in April 2017.
- Further expansion plans include the introduction of a medical purposes food supplement product and a dermatology product in select EU countries commencing in May 2017.

**Market leading pharmaceutical processing and distribution of sophisticated delivery technologies**



- Headquartered in Israel, PhytoTech Therapeutics (PTL) is focused on low-cost, fast-to-market oral prescription drugs, developed from major active cannabinoids
- PTL lead products in development about to enter Phase 2 clinical studies, including;
  - PTL101 oral drug to treat seizures of paediatric patients with refractory epilepsy
  - PTL201 oral drug for treating spasticity related symptoms
- Successful outcomes from Phase 1 Clinical Trial include;
  - Confirmed PTL's capsules have a safe and tolerable profile with no significant side effects.
  - Relative bioavailability of PTL's oral formulations were shown to perform at least as good as the leading non-oral, buccal spray product that suffers from major drawbacks, such as mouth ulcerations, short shelf-life at 4C, high inter and intra patient variability.

**Clinical Development of World-Class Oral Cannabinoid Products**

***Focused on Fast-Tracking Growth***

- MMJ views the emerging Canadian recreational market as a significant near-term growth catalyst and as such is committed to capturing a strategic first-mover advantage as market is legalized in 2017
- Finalization of TSX-V RTO transaction and subsequent roll out of Canadian marketing strategy
- Commencement of cannabis cultivation in December 2016 with a view to rolling out aggressive expansion plan throughout 2017
- Duncan Facility cultivation to include simultaneous growing of multiple unique cannabis strains that previously have not been available to Canadian consumers
- Drive revenue and sales growth of the Company's exclusive Gelpell Capsules throughout key regulated markets in Europe
- Remains committed to successful execution of Phase 2 Clinical Trial in Israel